Increasing evidence suggests that white matter disorders based on myelin sheath impairment may underlie the neuropathological changes in schizophrenia. But it is unknown whether enhancing remyelination is a beneficial approach to schizophrenia. To investigate this hypothesis, we used clemastine, an FDA-approved drug with high potency in promoting oligodendroglial differentiation and myelination, on a cuprizone-induced mouse model of demyelination. The mice exposed to cuprizone (0.2% in chow) for 6 weeks displayed schizophrenia-like behavioral changes, including decreased exploration of the center in the open fi eld test and increased entries into the arms of the Y-maze, as well as evident demyelination in the cortex and corpus callosum. Clemastine treatment was initiated upon cuprizone withdrawal at 10 mg/kg per day for 3 weeks. As expected, myelin repair was greatly enhanced in the demyelinated regions with increased mature oligodendrocytes (APC-positive) and myelin basic protein. More importantly, the clemastine treatment rescued the schizophrenia-like behavioral changes in the open field test and the Y-maze compared to vehicle, suggesting a beneficial effect via promoting myelin repair. Our fi ndings indicate that enhancing remyelination may be a potential therapy for schizophrenia.
INTRODUCTION
Dysfunctional neuronal communication may be the neuropathological basis of schizophrenia [1] [2] [3] [4] . Increasing evidence has suggested that abnormalities of myelin sheaths prominently contribute to the disturbance of neuronal circuits [5, 6] . A myelin sheath is a structure of compact multiple concentric cell membrane produced by oligodendrocytes (OLs) that wrap an axon segment in the central nervous system (CNS). As an essential component of the plasticity of neuronal circuits, myelin sheaths insulate and propagate electrical signals rapidly along axons [7] . More importantly, properly myelinated nerve fibers allow precise and accurate information to fl ow within and between neuronal circuits [3, 8, 9] . A number of imaging studies have shown that the white matter volume of schizophrenic brains is lower than in healthy controls, suggesting that myelin sheath damage or demyelination is involved in the schizophrenic brain [10] [11] [12] [13] [14] [15] . In line with this hypothesis, microarray analyses have shown that genes down-regulated in schizophrenic brains are related to OL development and myelination, arguing that myelin repair may be an unmet need that has been overlooked in therapies for schizophrenia [16] . [17] [18] [19] [20] , suggesting that myelin repair is benefi cial in the treatment of schizophrenia.
In response to demyelination or myelin sheath damage, myelin repair or remyelination can be complete, as OL precursors (OPCs) are present in the CNS throughout the entire lifetime and are intrinsically capable of differentiating into mature myelinating OLs [21] [22] [23] . Inhibitory cues in the microenvironment could handicap remyelination effi ciency of OPCs and result in remyelination failure. For instance, remyelination in the brain of multiple sclerosis patients may be incomplete due to the incapacity of OPC differentiation [24, 25] . In an attempt to promote remyelination, a high-throughput functional screening system using micropillar arrays has been developed lately and a cluster of muscarinic antagonists have been identified to be capable of promoting the differentiation and myelination by oligodendroglia in vivo [26, 27] . Among them, clemastine, an FDA-approved drug that can freely pass the bloodbrain barrier, is a potent compound that greatly enhances remyelination in a lysolecithin-or cuprizone-induced mouse model of demyelination [26, 27] .
Cuprizone-treated rodents display white matter damage and behavioral changes that may reflect anxiety and the cognitive defects induced by demyelination [17, 28, 29] .
Thus, in this study, the cuprizone-induced mouse model of demyelination was used to investigate the potential benefi cial effects of remyelination on schizophrenia. 
MATERIALS AND METHODS

Animals
Drug Treatments
Clemastine (Cat #: S1847; SelleckChem, Houston, TX) was dissolved in DMSO at 10 mg/mL before further dilution in distilled water. The fi nal concentration of DMSO was 0.004 v/v. After one week of acclimation, C57BL/6 mice were assigned to receive cuprizone (10 mg/kg per day) for six weeks or regular chow (n = 25 in each group), and fi ve mice from each group were sacrifi ced for histological examinations (Fig. 1A) ; the remaining mice were then exposed to either clemastine (n = 10 per group) or vehicle (0.004% DMSO v/v in distilled water) (n = 10 per group) at 10 mg/kg per day for three weeks. Each group was separately identifi ed and caged, and all mice were weighed weekly.
Immunostaining
Mice were deeply anaesthetized with sodium pentobarbital [18, 20, 28, 30] .
Y-Maze Task
The apparatus consisted of a Y-maze of three arms [17, 18, 20, 30] . Spontaneous alternation is the tendency to explore new arms over the one previously chosen. A set of sequent entries to three individual arms (e.g. ABC,
BCA, CAB) was counted as an alternation. The alternation measure was calculated as the percentage: Percent alternation = (number of alternations)/(total number of arm entries−2) ×100% [17] .
Stati stical Analysis
Data are expressed as mean ± SEM. All quantitative data were analyzed by one-way analysis of variance (ANOVA).
Comparisons between two experimental groups were made using Student's t-test [18, 28] . A significant difference was indicated when the P-value was <0.05.
RESULTS AND DISCUSSION
To determine the demyelination induced by cuprizone,
we assessed the MBP expression in the corpus callosum and cortex at the end of the 6-week exposure to cuprizone (Fig. 1A) . The intensity of MBP expression in the corpus callosum was decreased by 70% and in the cortex by 80% in the cuprizone model compared to the control animals, demonstrating a demyelinating response to cuprizone (Fig. 1B, C) . Clemastine was given to the mice for 3 weeks after the 6-week exposure to cuprizone (Fig.   1D ). We then found an evident 2-fold increase of MBP expression in the corpus callosum (Fig. 1E ), the cortex (Fig. 1F) , and the hippocampus (Fig. 1G ) compared to the vehicle-treated brain. No significant difference was seen between the control brains with clemastine versus those with vehicle treatment (Fig. 1E-G) , demonstrating that clemastine enhances remyelination in the cuprizone model of demyelination.
To understand the effect of clemastine on the oligodendroglial lineage, mature OLs were counted by APC immunostaining. The number of mature APC+ OLs was decreased to ~30% in the cortex ( Fig. 2A ) and corpus callosum ( Fig. 2B ) after exposure to cuprizone for 6 weeks.
After 3 weeks of clemastine treatment, a ~50% increase in the number of mature OLs was found in the cortex ( Fig.   2C ) and corpus callosum (Fig. 2D ) compared to vehicle.
Besides, clemastine treatment did not change the number of APC+ cells in control mice (Fig. 2C,D) . As the increased number of mature OLs was due to the differentiation of adult OPCs, we evaluated the OPC density in the brain by counting the PDGFRα-positive cells, and the OPC number in the clemastine treatment group did not significantly differ from the vehicle group (Fig. 2E) , suggesting that clemastine does not change the OPC population in the brain, and the myelin repair is due to its positive effect on the differentiation of OLs.
Behavioral tests were carried out after 0, 1, and 3 weeks of clemastine treatment (Fig. 3A) . The total distance traveled showed no significant difference between the clemastine treatment and vehicle groups, indicating that motor function in the cuprazone-treated animals was independent of the cuprizone-induced CNS demyelination (Fig. 3B) . To evaluate whether myelin impairment was positively associated with the behavioral defects in the cuprizone model, the open-field test was used to assess anxiety-like behavioral changes by measuring the distance traveled in the central area [18, 20, 28, 30] . It has been suggested that a decrease of exploration in the central area reflects Impairments of spatial working memory have been reported in the cuprizone model and in schizophrenic patients [18, 20, 30] . To measure the spatial working memory in the cuprizone model, we counted the arm entries. As expected, the mice with cuprizone-induced demyelination had significantly increased arm entries and decreased alternations, suggesting impaired spatial memory at the end of six weeks of cuprizone exposure caused by demyelination (Fig. 4) . Interestingly, clemastine treatment 622 for 3 weeks significantly decreased the arm entries ( Fig.   4A ) and increased behavioral alternations (Fig. 4B), suggesting that clemastine rescues the spatial memory impairments by enhancing remyelination.
Myelin sheaths play an important role in insulating axons and propagating electrical signals rapidly. Recent studies have shown that myelination is essential for social experience-based cognition and motor skill learning [31] [32] [33] [34] [35] [36] , abnormalities of the myelin sheath may contribute to defects of neuronal function. Increasing evidence has shown that the impairment of white matter integrity is prominent in schizophrenic brains [10, 11, 14, 15] and further underscores the importance of the myelin sheath in schizophrenia, pointing to myelin repair as a potential therapeutic strategy for schizophrenia. In support of this notion, quetiapine, an atypical anti-schizophrenic drug, has been found to be potent in promoting the differentiation of OLs in vitro and enhancing remyelination in mouse models of demyelination [17] [18] [19] [20] .
In the present study, we used clemastine as the reagent to promote remyelination in the cuprizone-induced demyelination model, given that it is potent in promoting remyelination and also passes the blood-brain barrier.
As expected, clemastine was capable of promoting remyelination, suggesting that it may be used for this purpose.
Cuprizone induces global demyelination in the brain and has been widely used to investigate the mechanisms of remyelination. A number of reports have indicated that this demyelination model also displays abnormal behaviors and cognitive defects that are believed to be a direct result of demyelination [28, 29, 37, 38] . The behavior changes may reflect neuronal abnormalities, like anxiety and cognitive impairment, and mimic, at least partially, schizophrenia symptoms in humans. It has been well documented that quetiapine rescues the behavioral changes in the cuprizone-induced animal model of demyelination, presumably by promoting remyelination or protecting myelin from breakdown [17, 18] . Quetiapine targets multiple receptors, including dopaminergic, serotoninergic, adrenergic, and histaminergic receptors [20] . Given the non-specific binding affinity, it is possible that the effect of quetiapine on behavioral changes is independent of the enhanced 
